Four profiles of patient for whom I prescript rupatadine Review article
Article Sidebar
Main Article Content
Abstract
In this paper we are presenting four patients’ profiles, when treatment with rupatadine might be very effective. Our review is based on older and new clinical trials.
Downloads
Download data is not yet available.
Article Details
How to Cite
Pawliczak, R. (2022). Four profiles of patient for whom I prescript rupatadine. Alergoprofil, 18(3), 3-5. https://doi.org/10.24292/01.AP.183300922
Issue
Section
THERAPY
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Solans A, Izquierdo I, Donado E et al. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. Clin Ther. 2008; 30(9): 1639-50.
2. Valero A, Serrano C, Bartrá J et al. Reduction of nasal volume after allergen-induced rhinitis in patients treated with rupatadine: a randomized, cross-over, double-blind, placebo- controlled study. J Investig Allergol Clin Immunol. 2009; 19(6): 488-93.
3. Vasiadi M, Kalogeromitros D, Kempuraj D et al. Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. Int Arch Allergy Immunol. 2010; 151(1): 38-45.
4. Mion de Godoy O, Campos RA, Antila M et al. Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis. Braz J Otorhinolaryngol. 2009; 75(5): 673-9.
5. Okubo K, Suzuki T, Tanaka A et al. Long-term safety and efficacy of rupatadine in Japanese patients with perennial allergic rhinitis: a 52-week open-label clinical trial. J Drug Assess. 2019; 8(1): 104-14.
6. Valero A, de la Torre F, Castillo JA et al. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain. Drug Saf. 2009; 32(1): 33-42.
7. Won TB, Kim HG, Kim JW et al. Efficacy and safety of rupatadine fumarate in the treatment of perennial allergic rhinitis: A multicenter, double-blinded, randomized, placebo-controlled, bridging study in Koreans. Asian Pac J Allergy Immunol. 2021.
8. Compalati E, Canonica GW. Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Curr Med Res Opin. 2013; 29(11): 1539-519.
9. Eloy Ph, Tobback L, Imschoot L. Rupatadine relieves allergic rhinitis: a prospective observational study. B-ENT. 2015; 11(1): 11-8.
10. Gonzalez-Nunez V, Bachert C, Mullol J. Rupatadine: global safety evaluation in allergic rhinitis and urticaria. Expert Opin Drug Saf. 2016; 15(10): 1439-48.
11. Katiyar S, Prakash S. Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis. Prim Care Respir J. 2009; 18(2): 57-68.
12. Shamizadeh S, Brockow K, Ring J. Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects. Allergo J Int. 2014; 23(3): 87-95.
13. Taubel J, Ferber G, Fernandes S et al. Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo- Controlled Trial. PLoS One. 2016; 11(9): e0163020.
2. Valero A, Serrano C, Bartrá J et al. Reduction of nasal volume after allergen-induced rhinitis in patients treated with rupatadine: a randomized, cross-over, double-blind, placebo- controlled study. J Investig Allergol Clin Immunol. 2009; 19(6): 488-93.
3. Vasiadi M, Kalogeromitros D, Kempuraj D et al. Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. Int Arch Allergy Immunol. 2010; 151(1): 38-45.
4. Mion de Godoy O, Campos RA, Antila M et al. Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis. Braz J Otorhinolaryngol. 2009; 75(5): 673-9.
5. Okubo K, Suzuki T, Tanaka A et al. Long-term safety and efficacy of rupatadine in Japanese patients with perennial allergic rhinitis: a 52-week open-label clinical trial. J Drug Assess. 2019; 8(1): 104-14.
6. Valero A, de la Torre F, Castillo JA et al. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain. Drug Saf. 2009; 32(1): 33-42.
7. Won TB, Kim HG, Kim JW et al. Efficacy and safety of rupatadine fumarate in the treatment of perennial allergic rhinitis: A multicenter, double-blinded, randomized, placebo-controlled, bridging study in Koreans. Asian Pac J Allergy Immunol. 2021.
8. Compalati E, Canonica GW. Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Curr Med Res Opin. 2013; 29(11): 1539-519.
9. Eloy Ph, Tobback L, Imschoot L. Rupatadine relieves allergic rhinitis: a prospective observational study. B-ENT. 2015; 11(1): 11-8.
10. Gonzalez-Nunez V, Bachert C, Mullol J. Rupatadine: global safety evaluation in allergic rhinitis and urticaria. Expert Opin Drug Saf. 2016; 15(10): 1439-48.
11. Katiyar S, Prakash S. Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis. Prim Care Respir J. 2009; 18(2): 57-68.
12. Shamizadeh S, Brockow K, Ring J. Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects. Allergo J Int. 2014; 23(3): 87-95.
13. Taubel J, Ferber G, Fernandes S et al. Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo- Controlled Trial. PLoS One. 2016; 11(9): e0163020.